Warp Sciences to Build Robotics-Powered Drug Discovery Research Platform, Raises $215 Million

The Robot Report reported on Oct. 28, 2026, that Warp Sciences had emerged from stealth and announced plans to build a platform for drug discovery research. The company raised $215 million and plans to establish a U.S.-based contract research organization (CRO) specializing in chemistry. It will combine chemists, robots and AI to synthesize and test molecules for research teams.

Warp Sciences says it will build a platform that synthesizes and tests molecules for research teams rather than developing its own drug candidates. Its plan integrates contract experimental services with the generation of data for AI training, addressing how research organizations connect experiments with model improvement.

The company disclosed a funding total of $215 million, but the information provided does not specify how much will go toward laboratory equipment, robots or AI development. The amount alone is not enough to assess the scale of automation or experimental throughput. The business model’s distinguishing feature is that, rather than owning drug candidates, the company will provide outside researchers with the capability to make and test molecules, then feed the resulting data back into improvements to its AI and laboratories. In this cycle, not only the volume of experimental data but also which experimental conditions and results are used to train the models will matter. However, the information provided does not explain data rights or sharing, what the AI will be trained on, or experimental reproducibility. The company’s description of automating workflows one by one while chemists continue working also differs from a plan to make every process fully autonomous at once. The extent of laboratory mechanization cannot be assessed without examining the automation rate and the processes covered at each stage. When evaluating physical AI, separating the performance of computational models from data collection and evaluation in real-world environments also connects to the issues in tactile sensing covered in Leaderobot.com reports on developments around MoKan Technology’s full-body electronic skin. However, Warp Sciences focuses on chemical experiments and does not demonstrate the same mechanisms as robot tactile technology. Its metrics also differ from the production-capacity target discussed in Tesla reportedly begins initial Optimus production at Fremont, targets capacity of 20,000 units a week. For Warp Sciences, assessment will require examining not only the funding and automation plans but also the number of experiments actually conducted, the automation scope for each process, and how AI-generated experimental proposals translate into research results. Information provided so far also does not specify laboratory operations, throughput or data handling.

Co-founder and CEO Kevin Weil said on LinkedIn that the funding was a Series A round led by Lightspeed. The company says it is building a platform for researchers engaged in drug discovery rather than developing its own drug candidates. According to the company, chemists will initially conduct experiments, and the company will automate their work one task at a time. It plans to use experimental data to train AI, then use the improved AI to design experiments and advance laboratory automation. The laboratory is reported to be in South San Francisco.